News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Epigenomics AG 

26.06.2015 09:15

Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------


Voting Rights: Release of Voting Rights Notifications (§ 21 para. 1 WpHG)
in Accordance with § 26 para. 1 WpHG (German Securities Trading Act) with
the Aim of an Europe-wide Distribution

Issuer: 
 
Epigenomics AG 
- ISIN DE000A11QW50 - 
Geneststr. 5
10829 Berlin 
Deutschland 
 
Voting Rights Notifications:
 
 1. On 24 June 2015, James E. Flynn, USA, notified Epigenomics AG of voting
    rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG as follows:

On 22 June 2015, as a consequence of the acquisition of shares to which
voting rights are attached, the share of James E. Flynn in the voting
rights of Epigenomics AG exceeded the 3 per cent threshold of sec. 21 para.
1 WpHG and amounted, as at this date, to 3.06 per cent of the voting rights
(535,169 voting rights) in Epigenomics AG.

All 3.06 per cent of the voting rights (535,169 voting rights) are
attributed to James E. Flynn pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG
through the following entities controlled by James E. Flynn and holding 3
per cent or more of the voting rights in Epigenomics AG:

  - J.E. Flynn Capital, LLC
  - Deerfield Mgmt, L.P.
  - Deerfield Special Situations Fund, L.P.

All 3.06 per cent of the voting rights (535,169 voting rights) are held
directly by Deerfield Special Situations Fund, L.P. and are additionally
attributed to James E. Flynn pursuant to sec. 22 para. 1 sent. 1 no. 6 WpHG
in connection with sec. 22 para. 1 sent. 2 WpHG.

 2. Furthermore, on 24 June 2015, J.E. Flynn Capital, LLC, Wilmington,
    Delaware, USA, notified Epigenomics AG of voting rights in Epigenomics
    AG pursuant to sec. 21 para. 1 WpHG as follows:

On 22 June 2015, as a consequence of the acquisition of shares to which
voting rights are attached, the share of J.E. Flynn Capital, LLC in the
voting rights of Epigenomics AG exceeded the 3 per cent threshold of sec.
21 para. 1 WpHG and amounted, as at this date, to 3.06 per cent of the
voting rights (535,169 voting rights) in Epigenomics AG.

All 3.06 per cent of the voting rights (535,169 voting rights) are
attributed to J.E. Flynn Capital, LLC pursuant to sec. 22 para. 1 sent. 1
no. 1 WpHG through the following entities controlled by J.E. Flynn Capital,
LLC and holding 3 per cent or more of the voting rights in Epigenomics AG:

  - Deerfield Mgmt, L.P.
  - Deerfield Special Situations Fund, L.P.

 3. Furthermore, on 24 June 2015, Deerfield Mgmt, L.P., Wilmington,
    Delaware, USA, notified Epigenomics AG of voting rights in Epigenomics
    AG pursuant to sec. 21 para. 1 WpHG as follows:

On 22 June 2015, as a consequence of the acquisition of shares to which
voting rights are attached, the share of Deerfield Mgmt, L.P. in the voting
rights of Epigenomics AG exceeded the 3 per cent threshold of sec. 21 para.
1 WpHG and amounted, as at this date, to 3.06 per cent of the voting rights
(535,169 voting rights) in Epigenomics AG.

All 3.06 per cent of the voting rights (535,169 voting rights) are
attributed to Deerfield Mgmt, L.P. pursuant to sec. 22 para. 1 sent. 1 no.
1 WpHG through the following entity controlled by Deerfield Mgmt, L.P. and
holding 3 per cent or more of the voting rights in Epigenomics AG:

  - Deerfield Special Situations Fund, L.P.

 4. Furthermore, on 24 June 2015, Deerfield Special Situations Fund, L.P.,
    Wilmington, Delaware, USA, notified Epigenomics AG of voting rights in
    Epigenomics AG pursuant to sec. 21 para. 1 WpHG as follows:

On 22 June 2015, as a consequence of the acquisition of shares to which
voting rights are attached, the share of Deerfield Special Situations Fund,
L.P. in the voting rights of Epigenomics AG exceeded the 3 per cent
threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 3.06
per cent of the voting rights (535,169 voting rights) in Epigenomics AG.

 5. Furthermore, on 24 June 2015, Flynn Management, LLC, Wilmington,
    Delaware, USA, notified Epigenomics AG of voting rights in Epigenomics
    AG pursuant to sec. 21 para. 1 WpHG as follows:

On 22 June 2015, as a consequence of the acquisition of shares to which
voting rights are attached, the share of Flynn Management, LLC in the
voting rights of Epigenomics AG exceeded the 3 per cent threshold of sec.
21 para. 1 WpHG and amounted, as at this date, to 3.06 per cent of the
voting rights (535,169 voting rights) in Epigenomics AG.

All 3.06 per cent of the voting rights (535,169 voting rights) are held
directly by Deerfield Special Situations Fund, L.P. and are attributed to
Flynn Management, LLC pursuant to sec. 22 para. 1 sent. 1 no. 6 WpHG in
connection with sec. 22 para. 1 sent. 2 WpHG.

 6. Furthermore, on 24 June 2015, Deerfield Management Company, L.P.,
    Wilmington, Delaware, USA, notified Epigenomics AG of voting rights in
    Epigenomics AG pursuant to sec. 21 para. 1 WpHG as follows:

On 22 June 2015, as a consequence of the acquisition of shares to which
voting rights are attached, the share of Deerfield Management Company, L.P.
in the voting rights of Epigenomics AG exceeded the 3 per cent threshold of
sec. 21 para. 1 WpHG and amounted, as at this date, to 3.06 per cent of the
voting rights (535,169 voting rights) in Epigenomics AG.

  - All 3.06 per cent of the voting rights (535,169 voting rights) are held
    by Deerfield Special Situations Fund, L.P. and are attributed to
    Deerfield Management Company, L.P. pursuant to sec. 22 para. 1 sent. 1
    no. 6 WpHG.

Date of release: 26 June 2015 
 
Epigenomics AG 
The Executive Board 


Contact:  

Epigenomics AG
Antje Zeise
Manager Investor Relations
Tel.: +49 (0)30 24345 386
Fax: +49 (0)30 24345 555
Email: antje.zeise@epigenomics.com  



26.06.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Epigenomics AG
              Geneststraße 5
              10829 Berlin
              Germany
Internet:     www.epigenomics.com
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------